{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:39:16Z","timestamp":1790840356566,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00428-022-03430-4","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T08:04:52Z","timestamp":1666253092000},"page":"27-37","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["The International Consensus Classification of acute myeloid leukemia"],"prefix":"10.1007","volume":"482","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4250-3891","authenticated-orcid":false,"given":"Olga K.","family":"Weinberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Porwit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Orazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Hasserjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Foucar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Duncavage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Arber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"issue":"20","key":"3430_CR1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"4","key":"3430_CR2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","volume":"33","author":"JM Bennett","year":"1976","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al (1976) Proposals for the classification of the acute leukaemias French-American-British (FAB) co-operative group. Br J Haematol 33(4):451\u2013458","journal-title":"Br J Haematol"},{"key":"3430_CR3","doi-asserted-by":"publisher","unstructured":"Arber DA, Orazi A, Hasserjian RP (2022) International Consensus Classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood blood 2022015850. https:\/\/doi.org\/10.1182\/blood.2022015850.","DOI":"10.1182\/blood.2022015850"},{"key":"3430_CR4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1309\/AJCP58RSMFRHLHHH","volume":"144","author":"J Vardiman","year":"2015","unstructured":"Vardiman J, Reichard K (2015) Acute myeloid leukemia with myelodysplasia-related changes. Am J Clin Pathol 144:29\u201343","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"3430_CR5","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/ajh.25769","volume":"95","author":"G Montalban-Bravo","year":"2020","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM (2020) Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol 95(6):612\u2013622","journal-title":"Am J Hematol"},{"issue":"10","key":"3430_CR6","first-page":"869","volume":"43","author":"F Mannelli","year":"2015","unstructured":"Mannelli F, Ponziani V, Bonetti MI, Bencini S, Cutini I, Gianfaldoni G, Scappini B et al (2015) Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemiaExp. Hematol 43(10):869-879 e22","journal-title":"Hematol"},{"issue":"10","key":"3430_CR7","doi-asserted-by":"crossref","first-page":"8388","DOI":"10.18632\/oncotarget.3460","volume":"6","author":"R Devillier","year":"2015","unstructured":"Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet J, Bertoli S, Brecqueville M, Arnoulet C et al (2015) Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. Oncotarget 6(10):8388\u20138396","journal-title":"Oncotarget"},{"issue":"15","key":"3430_CR8","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2010-04-279794","volume":"116","author":"M Miesner","year":"2010","unstructured":"Miesner M, Haferlach C, Bacher U, Weiss T, Macijewski K, Kohlmann K et al (2010) Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS\/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as \u201cAML not otherwise specified\u201d (AML-NOS) or \u201cAML with myelodysplasia-related changes\u201d (AML-MRC). Blood 116(15):2742\u20132751","journal-title":"Blood"},{"issue":"9","key":"3430_CR9","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/blood-2008-10-182782","volume":"113","author":"OK Weinberg","year":"2009","unstructured":"Weinberg OK, Seetharam M, Ren L, Seo K, Ma L, Merker JD, Gotlib J, Zehnder JL, Arber DA (2009) Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood 113(9):1906\u20131908","journal-title":"Blood"},{"issue":"22","key":"3430_CR10","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"Cancer Genome Atlas Research Network Ley TJ Miller C, Ding L et al","year":"2013","unstructured":"Cancer Genome Atlas Research Network Ley TJ Miller C, Ding L et al (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368(22):2059\u20132074","journal-title":"N Engl J Med"},{"issue":"4","key":"3430_CR11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447","journal-title":"Blood"},{"key":"3430_CR12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, Grauman PV et al (2015) Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125:1367\u20131376","journal-title":"Blood"},{"key":"3430_CR13","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374:2209\u20132221","journal-title":"N Engl J Med"},{"issue":"5","key":"3430_CR14","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/ajcp\/aqab172","volume":"157","author":"Y Gao","year":"2022","unstructured":"Gao Y, Jia M, Mao Y, Cai H, Jiang X, Cao X, Zhou D, Li J (2022) Distinct mutation landscapes between acute myeloid leukemia with myelodysplasia-related changes and de novo acute myeloid leukemia. Am J Clin Pathol 157(5):691\u2013700","journal-title":"Am J Clin Pathol"},{"issue":"Supplement 1","key":"3430_CR15","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1182\/blood-2019-128234","volume":"134","author":"C Baer","year":"2019","unstructured":"Baer C, Walter W, Stengel A, Hutter S, Meggendorfer M, Kern W, Haferlach C, Haferlach T (2019) Molecular classification of AML-MRC reveals a distinct profile and identifies MRC-like patients with poor overall survival. Blood 134(Supplement 1):2735","journal-title":"Blood"},{"issue":"26","key":"3430_CR16","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1182\/blood-2009-05-223784","volume":"114","author":"JL Tang","year":"2009","unstructured":"Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MS et al (2009) AML1\/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 114(26):5352\u20135361","journal-title":"Blood"},{"issue":"25","key":"3430_CR17","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2011.40.6652","volume":"30","author":"JH Mendler","year":"2012","unstructured":"Mendler JH, Maharry K, Radmacher MD, Mr\u00f3zek K, Becker H, Metzeler KH et al (2012) RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. J Clin Oncol 30(25):3109\u20133111","journal-title":"J Clin Oncol"},{"issue":"6","key":"3430_CR18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/ajcp\/aqaa107","volume":"154","author":"DA Arber","year":"2020","unstructured":"Arber DA, Erba HP (2020) Diagnosis and treatment of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC). Am J Clin Pathol 154(6):731\u2013741","journal-title":"Am J Clin Pathol"},{"key":"3430_CR19","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1186\/s12885-017-3803-6","volume":"17","author":"JF Seymour","year":"2017","unstructured":"Seymour JF, D\u00f6hner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R et al (2017) Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. BMC Cancer 17:852","journal-title":"BMC Cancer"},{"issue":"8","key":"3430_CR20","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/genes11080845","volume":"11","author":"KL Koenig","year":"2020","unstructured":"Koenig KL, Sahasrabudhe KD, Sigmund AM, Bhatnagar B (2020) AML with myelodysplasia-related changes: development, challenges, and treatment advances. Genes (Basel) 11(8):845","journal-title":"Genes (Basel)"},{"issue":"5","key":"3430_CR21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2013.096420","volume":"99","author":"HJ Rogers","year":"2014","unstructured":"Rogers HJ, Vardiman JW, Anastasi J, Raca G, Savage NM, Cherry AM, Arber DA et al (2014) Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)\/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica 99(5):821\u20139","journal-title":"Haematologica"},{"key":"3430_CR22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK (2010) National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354\u2013365","journal-title":"Blood"},{"key":"3430_CR23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1309\/AJCPMLO84JDNVLNK","volume":"142","author":"OK Weinberg","year":"2014","unstructured":"Weinberg OK, Ohgami RS, Ma L, Seo K, Ren L, Gotlib J, Seetharam M, Cherry A, Arber DA (2014) Acute myeloid leukemia with monosomal karyotype: morphologic, immunophenotypic, and molecular findings. Am J Clin Pathol 142:190\u2013195","journal-title":"Am J Clin Pathol"},{"key":"3430_CR24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood-2011-07-367508","volume":"119","author":"S Kayser","year":"2012","unstructured":"Kayser S, Zucknick M, D\u00f6hner K, Krauter J, K\u00f6hne CH, Horst HA et al (2012) Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood 119:551\u2013558","journal-title":"Blood"},{"key":"3430_CR25","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","volume":"26","author":"DA Breems","year":"2008","unstructured":"Breems DA, Putten WLJV, Greef GED, Zelderen-Bhola SLV, Gerssen-Schoorl KBJ, Mellink CHM et al (2008) Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 26:4791\u20134797","journal-title":"J Clin Oncol"},{"key":"3430_CR26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1309\/B4NVER1AJJ84CTUU","volume":"127","author":"CP Soupir","year":"2007","unstructured":"Soupir CP, Vergilio JA, Dal Cin P, Muzikansky A, Kantarjian H, Jones D, Hasserjian RP (2007) Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol 127:642\u2013650","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"3430_CR27","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.5858\/arpa.2016-0059-RA","volume":"140","author":"HY Wang","year":"2016","unstructured":"Wang HY, Rashidi HH (2016) The new clinicopathologic and molecular findings in myeloid neoplasms with inv(3)(q21q26)\/t(3;3)(q21;q26.2). Arch Pathol Lab Med 140(12):1404\u20131410","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"3430_CR28","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1080\/10428194.2020.1737689","volume":"61","author":"I Summerer","year":"2020","unstructured":"Summerer I, Haferlach C, Meggendorfer M, Kern W, Haferlach T, Stengel A (2020) Prognosis of MECOM ( EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count. Leuk Lymphoma 61(7):1756\u20131759","journal-title":"Leuk Lymphoma"},{"key":"3430_CR29","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2019000090","volume":"3","author":"SS Patel","year":"2019","unstructured":"Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT et al (2019) Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Adv 3:1540\u20131545","journal-title":"Blood Adv"},{"key":"3430_CR30","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","volume":"3","author":"G Montalban-Bravo","year":"2019","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E et al (2019) NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv 3:922\u2013933","journal-title":"Blood Adv"},{"issue":"4","key":"3430_CR31","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2003-02-0477","volume":"102","author":"K Keeshan","year":"2003","unstructured":"Keeshan K, Santilli G, Corradini F, Perrotti D, Calabretta B (2003) Transcription activation function of C\/EBPalpha is required for induction of granulocytic differentiation. Blood 102(4):1267\u20131275","journal-title":"Blood"},{"issue":"2","key":"3430_CR32","doi-asserted-by":"crossref","first-page":"e1900178","DOI":"10.1002\/bies.201900178","volume":"42","author":"L Schmidt","year":"2020","unstructured":"Schmidt L, Heyes E, Grebien F (2020) Gain-of-function effects of N-terminal CEBPA mutations in acute myeloid leukemia. BioEssays 42(2):e1900178","journal-title":"BioEssays"},{"issue":"2","key":"3430_CR33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jmoldx.2010.09.001","volume":"13","author":"V Grossmann","year":"2011","unstructured":"Grossmann V, Schnittger S, Schindela S, Klein H-U, Eder C, Dugas M, Kern W, Haferlach T, Haferlach C, Kohlmann A (2011) Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology. J Mol Diagn 13(2):129\u2013136","journal-title":"J Mol Diagn"},{"issue":"13","key":"3430_CR34","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2008-09-179895","volume":"113","author":"BJ Wouters","year":"2009","unstructured":"Wouters BJ, L\u00f6wenberg B, Erpelinck-Verschueren CAJ, van Wim LJ, Putten P, Valk JM, Delwel R (2009) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113(13):3088\u20133091","journal-title":"Blood"},{"issue":"1","key":"3430_CR35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/blood.2020009680","volume":"139","author":"F Taube","year":"2022","unstructured":"Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, R\u00f6llig C et al (2022) CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood 139(1):87\u2013103","journal-title":"Blood"},{"issue":"13","key":"3430_CR36","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood.2020009652","volume":"138","author":"K Tarlock","year":"2021","unstructured":"Tarlock K, Lamble AJ, Wang YC, Gerbing RB, Ries RE, Loken M et al (2021) CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children\u2019s Oncology Group. Blood 138(13):1137\u20131147","journal-title":"Blood"},{"issue":"1","key":"3430_CR37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/cdd.2017.185","volume":"25","author":"MP Kim","year":"2018","unstructured":"Kim MP, Lozano G (2018) Mutant p53 partners in crime. Cell Death Differ 25(1):161\u2013168","journal-title":"Cell Death Differ"},{"issue":"9","key":"3430_CR38","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/humu.23035","volume":"37","author":"L Bouaoun","year":"2016","unstructured":"Bouaoun L, Sonkin D, Ardin M (2016) Monica Hollstein 3 4, Graham Byrnes 1, Jiri Zavadil 3, Magali Olivier 3 TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat 37(9):865\u2013876","journal-title":"Hum Mutat"},{"issue":"1","key":"3430_CR39","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","volume":"13","author":"Y Tazi","year":"2022","unstructured":"Tazi Y, Arango-Ossa JE, Zhou Y, Bernard E, Thomas I, Gilkes A et al (2022) Unified classification and risk-stratification in acute myeloid leukemia. Nat Commun 13(1):4622","journal-title":"Nat Commun"},{"key":"3430_CR40","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C et al (2013) Mutational landscape and significance across 12 major cancer types. Nature 502:333\u2013339","journal-title":"Nature"},{"issue":"6","key":"3430_CR41","first-page":"305","volume":"10","author":"V Marchesi","year":"2013","unstructured":"Marchesi V (2013) Genetics: the AML mutational landscape. Nat Rev Clin Oncol 10(6):305","journal-title":"Nat Rev Clin Oncol"},{"key":"3430_CR42","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood-2016-11-749903","volume":"129","author":"G Montalban-Bravo","year":"2017","unstructured":"Montalban-Bravo G, Benton CB, Wang SA, Ravandi F, Kadia T, Cortes J et al (2017) More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood 129:2584\u20132587","journal-title":"Blood"},{"issue":"4","key":"3430_CR43","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447","journal-title":"Blood"},{"issue":"15","key":"3430_CR44","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood.2022015709","volume":"139","author":"JS Welch","year":"2022","unstructured":"Welch JS (2022) TP53 and the star-crossed lovers MDS and AML. Blood 139(15):2265\u20132266","journal-title":"Blood"},{"issue":"8","key":"3430_CR45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-015-0139-z","volume":"8","author":"CY Ok","year":"2015","unstructured":"Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, Goswami M, Young KH, Singh R, Medeiros LJ, Kantarjian HM, Luthra R, Wang SA (2015) TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol 8(8):45","journal-title":"J Hematol Oncol"},{"key":"3430_CR46","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS et al (2020) Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med 26:1549\u20131556","journal-title":"Nat Med"},{"issue":"15","key":"3430_CR47","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","volume":"139","author":"T Grob","year":"2022","unstructured":"Grob T, Al Hinai ASA, Sanders MA, Kavelaars FG, Rijken M, Gradowska PL et al (2022) Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 139(15):2347\u20132354","journal-title":"Blood"},{"issue":"9","key":"3430_CR48","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","volume":"6","author":"OK Weinberg","year":"2022","unstructured":"Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber DA, Dal Cin P et al (2022) TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML. Blood Adv 6(9):2847\u20132853","journal-title":"Blood Adv"},{"key":"3430_CR49","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.5858\/arpa.2016-0504-CP","volume":"141","author":"DA Arber","year":"2017","unstructured":"Arber DA, Borowitz MJ, Cessna M, Etzell J, Foucar K, Hasserjian RP et al (2017) Initial diagnostic workup of acute leukemia: guideline from the College of American Pathologists and the American Society of Hematology. Arch Pathol Lab Med 141:1342\u20131393","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"3430_CR50","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/sj.leu.2402504","volume":"16","author":"O Hrus\u00e1k","year":"2002","unstructured":"Hrus\u00e1k O, Porwit-MacDonald A (2002) Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 16(7):1233\u20131258","journal-title":"Leukemia"},{"issue":"7","key":"3430_CR51","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2013.03.009","volume":"37","author":"YR Liu","year":"2013","unstructured":"Liu YR, Zhu HH, Ruan GR, Qin YZ, Shi HX, Lai YY, Chang Y, Wang YZ, Lu D, Hao L, Li JL, Li LD, Jiang B, Huang XJ (2013) NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes. Leuk Res 37(7):737\u2013741","journal-title":"Leuk Res"},{"issue":"4","key":"3430_CR52","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/cyto.b.21979","volume":"100","author":"M Gupta","year":"2021","unstructured":"Gupta M, Jafari K, Rajab A, Wei C, Mazur J, Tierens A, Hyjek E, Musani R, Porwit A (2021) Radar plots facilitate differential diagnosis of acute promyelocytic leukemia and NPM1+ acute myeloid leukemia by flow cytometry. Cytometry B Clin Cytom 100(4):409\u2013420","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"3430_CR53","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/cyto.b.21219","volume":"92","author":"S Matarraz","year":"2017","unstructured":"Matarraz S, Almeida J, Flores-Montero J, L\u00e9crevisse Q, Guerri V, L\u00f3pez A, B\u00e1rrena S, Van Der Velden V, Te Marvelde JG, Van Dongen JJM, Orfao A (2017) Introduction to the diagnosis and classification of monocytic-lineage leukemias by flow cytometry. Cytometry B Clin Cytom 92(3):218\u2013227","journal-title":"Cytometry B Clin Cytom"},{"issue":"11","key":"3430_CR54","doi-asserted-by":"crossref","first-page":"726637","DOI":"10.3389\/fonc.2021.726637","volume":"31","author":"G Merati","year":"2021","unstructured":"Merati G, Rossi M, Gall\u00ec A, Roncoroni E, Zibellini S, Rizzo E, Pietra D, Picone C, Rocca B, Cabrera CPT, Gelli E, Santacroce E, Arcaini L, Zappasodi P (2021) Enrichment of double RUNX1 mutations in acute leukemias of ambiguous lineage. Front Oncol 31(11):726637","journal-title":"Front Oncol"},{"issue":"10","key":"3430_CR55","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood.2020007897","volume":"137","author":"W Xiao","year":"2021","unstructured":"Xiao W, Chan A, Waarts MR, Mishra T, Liu Y, Cai SF, Yao J, Gao Q, Bowman RL, Koche RP, Csete IS, DelGaudio NL, Derkach A, Baik J, Yanis S, Famulare CA, Patel M, Arcila ME, Stahl M, Rampal RK, Tallman MS, Zhang Y, Dogan A, Goldberg AD, Roshal M, Levine RL (2021) Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood 137(10):1377\u20131391","journal-title":"Blood"},{"key":"3430_CR56","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3390\/hemato2030036","volume":"2","author":"A Porwit","year":"2021","unstructured":"Porwit A, B\u00e9n\u00e9 MC (2021) The plasmacytoid dendritic cell CD123+ compartment in acute leukemia with or without RUNX1 mutation: high inter-patient variability disclosed by immunophenotypic unsupervised analysis and clustering. Hemato 2:572\u2013585","journal-title":"Hemato"},{"issue":"9","key":"3430_CR57","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/leu.2014.191","volume":"28","author":"A Porwit","year":"2014","unstructured":"Porwit A, van de Loosdrecht AA, Bettelheim P, Brodersen LE, Burbury K, Cremers E, Della Porta MG, Ireland R, Johansson U, Matarraz S, Ogata K, Orfao A, Preijers F, Psarra K, Subir\u00e1 D, Valent P, van der Velden VH, Wells D, Westers TM, Kern W, B\u00e9n\u00e9 MC (2014) Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International\/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia 28(9):1793\u20131798","journal-title":"Leukemia"},{"issue":"2","key":"3430_CR58","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/jclinpath-2016-203863","volume":"70","author":"OK Weinberg","year":"2017","unstructured":"Weinberg OK, Hasserjian RP, Li B, Pozdnyakova O (2017) Assessment of myeloid and monocytic dysplasia by flow cytometry in de novo AML helps define an AML with myelodysplasia-related changes category. J Clin Pathol 70(2):109\u2013115","journal-title":"J Clin Pathol"},{"issue":"12","key":"3430_CR59","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/jclinpath-2018-205348","volume":"71","author":"KC Dannheim","year":"2018","unstructured":"Dannheim KC, Pozdnyakova O, Dal Cin P, Weinberg OK (2018) Immunophenotypic dysplasia and aberrant T-cell antigen expression in acute myeloid leukaemia with complex karyotype and TP53 mutations. J Clin Pathol 71(12):1051\u20131059","journal-title":"J Clin Pathol"},{"issue":"45","key":"3430_CR60","doi-asserted-by":"crossref","first-page":"72685","DOI":"10.18632\/oncotarget.12234","volume":"7","author":"M Dimitriou","year":"2016","unstructured":"Dimitriou M, Woll PS, Mortera-Blanco T, Karimi M, Wedge DC, Doolittle H, Douagi I, Papaemmanuil E, Jacobsen SE, Hellstr\u00f6m-Lindberg E (2016) Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality. Oncotarget 7(45):72685\u201372698","journal-title":"Oncotarget"},{"issue":"4","key":"3430_CR61","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/cyto.b.21775","volume":"96","author":"X Chen","year":"2019","unstructured":"Chen X, Wood BL, Cherian S (2019) Immunophenotypic features of myeloid neoplasms associated with chromosome 7 abnormalities. Cytometry B Clin Cytom 96(4):300\u2013309","journal-title":"Cytometry B Clin Cytom"},{"issue":"7","key":"3430_CR62","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36(7):1703\u20131719","journal-title":"Leukemia"},{"issue":"1","key":"3430_CR63","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ajcp\/aqac070","volume":"158","author":"OK Weinberg","year":"2022","unstructured":"Weinberg OK, Arber DA (2022) How I diagnose acute leukemia of ambiguous lineage. Am J Clin Pathol 158(1):27\u201334","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"3430_CR64","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s11912-022-01252-w","volume":"24","author":"MC B\u00e9n\u00e9","year":"2022","unstructured":"B\u00e9n\u00e9 MC, Porwit A (2022) Mixed phenotype\/lineage leukemia: has anything changed for 2021 on diagnosis, classification, and treatment? Curr Oncol Rep 24(8):1015\u20131022","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"3430_CR65","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11912-020-01010-w","volume":"23","author":"TB Alexander","year":"2021","unstructured":"Alexander TB, Orgel E (2021) Mixed phenotype acute leukemia: current approaches to diagnosis and treatment. Curr Oncol Rep 23(2):22","journal-title":"Curr Oncol Rep"},{"issue":"7727","key":"3430_CR66","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41586-018-0436-0","volume":"562","author":"TB Alexander","year":"2018","unstructured":"Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, Payne-Turner D, Yoshihara H, Loh ML, Horan J, Buldini B, Basso G, Elitzur S, de Haas V, Zwaan CM, Yeoh A, Reinhardt D, Tomizawa D, Kiyokawa N, Lammens T, De Moerloose B, Catchpoole D, Hori H, Moorman A, Moore AS, Hrusak O, Meshinchi S, Orgel E, Devidas M, Borowitz M, Wood B, Heerema NA, Carrol A, Yang YL, Smith MA, Davidsen TM, Hermida LC, Gesuwan P, Marra MA, Ma Y, Mungall AJ, Moore RA, Jones SJM, Valentine M, Janke LJ, Rubnitz JE, Pui CH, Ding L, Liu Y, Zhang J, Nichols KE, Downing JR, Cao X, Shi L, Pounds S, Newman S, Pei D, Guidry Auvil JM, Gerhard DS, Hunger SP, Inaba H, Mullighan CG (2018) The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature 562(7727):373\u2013379","journal-title":"Nature"},{"issue":"14","key":"3430_CR67","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood-2012-09-454553","volume":"121","author":"S Bertoli","year":"2013","unstructured":"Bertoli S, B\u00e9rard E, Huguet F, Huynh A, Tavitian A, Vergez F et al (2013) Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood 121(14):2618\u20132626","journal-title":"Blood"},{"issue":"12","key":"3430_CR68","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","volume":"26","author":"A Burd","year":"2020","unstructured":"Burd A, Levine RL, Ruppert AS, Mims AS, Borate U, Stein EM (2020) Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med 26(12):1852\u20131858. https:\/\/doi.org\/10.1038\/s41591-020-1089-8","journal-title":"Nat Med"},{"issue":"12","key":"3430_CR69","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S et al (2018) Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131(12):1275\u20131291","journal-title":"Blood"},{"issue":"12","key":"3430_CR70","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ, Zhou S, Fu C et al (2020) Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and metaanalysis. JAMA Oncol 6(12):1890\u20131899","journal-title":"JAMA Oncol"},{"issue":"26","key":"3430_CR71","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, Tettero JM, Bachas C, Baer C, B\u00e9n\u00e9 MC, B\u00fccklein V, Czyz A, Denys B, Dillon R, Feuring-Buske M, Guzman ML, Haferlach T, Han L, Herzig JK, Jorgensen JL, Kern W, Konopleva MY, Lacombe F, Libura M, Majchrzak A, Maurillo L, Ofran Y, Philippe J, Plesa A, Preudhomme C, Ravandi F, Roumier C, Subklewe M, Thol F, van de Loosdrecht AA, van der Reijden BA, Venditti A, Wierzbowska A, Valk PJM, Wood BL, Walter RB, Thiede C, D\u00f6hner K, Roboz GJ, Cloos J (2021) 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138(26):2753\u20132767","journal-title":"Blood"},{"key":"3430_CR72","doi-asserted-by":"crossref","first-page":"103710","DOI":"10.1016\/j.critrevonc.2022.103710","volume":"175","author":"SK Khaldoyanidi","year":"2022","unstructured":"Khaldoyanidi SK, Hindoyan A, Stein A, Subklewe M (2022) Leukemic stem cells as a target for eliminating acute myeloid leukemia: gaps in translational research. Crit Rev Oncol Hematol 175:103710","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"3430_CR73","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cav\u00e9 H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, Gonz\u00e1lez M, Viehmann S, Malec M, Saglio G, van Dongen JJ (2003) Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 17(12):2318\u20132357","journal-title":"Leukemia"},{"issue":"9","key":"3430_CR74","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1080\/10428194.2020.1755855","volume":"61","author":"L Pettersson","year":"2020","unstructured":"Pettersson L, Chen Y, George AM, Rigo R, Lazarevic V, Juliusson G, Saal LH, Ehinger M (2020) Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis. Leuk Lymphoma 61(9):2168\u20132179","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"3430_CR75","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3390\/diagnostics12061305","volume":"12","author":"S Galimberti","year":"2022","unstructured":"Galimberti S, Balducci S, Guerrini F, Del Re M, Cacciola R (2022) Digital droplet PCR in hematologic malignancies: a new useful molecular tool. Diagnostics (Basel) 12(6):1305","journal-title":"Diagnostics (Basel)"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03430-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-022-03430-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-022-03430-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T14:21:06Z","timestamp":1674829266000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-022-03430-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3430"],"URL":"https:\/\/doi.org\/10.1007\/s00428-022-03430-4","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"assertion":[{"value":"18 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}